Products for Research Use Only

TKB272

CAT: 0804-HY-173148Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-173148Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg (K18-hACE2) 2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection[1].
CAS Number
2892688-18-3
UNSPSC
12352100
Target
SARS-CoV
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(N[C@H](C(N1C[C@H](C2(C)C)[C@H]2[C@H]1C(N[C@H](C(C3=NC(C=C(F)C=C4)=C4S3)=O)C[C@@H]5CCNC5=O)=O)=O)C(C)(C)C)C(F)(F)F
Molecular Formula
C30H35F4N5O5S
Molecular Weight
653.69
References & Citations
[1]Higashi-Kuwata N, et al. An orally available P1'-5-fluorinated M inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. PNAS Nexus. 2025 Jan 7;4 (1) :pgae578.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

Alternative Products